GBA Presents: RADIO SAVANT-!

stonedinvestor said:
Oh Van that's nothing my Mexico picks kicked out any Vietnam crap. The place to be where all the rich Chinese are going is Singapore<-- write it down.

But for businesses it's Mexico<-- write it down

But for consumer catch up it's China. <----

Hey we lost another guitarist>


RIP- Tom Verlaine
More...
Wasn't he married to Patti Smith for a bit? "Because the night--- belongs to lovers..." I think he was.
Anyway yeah... rip.

Why NIO Stoney? I mean is it just one of those stocks that everyone follows and one day its up and the next day its down.Have you done any homework on it? There's a hundred metrics to evaluate, or is this just a quick little trade for a few days? Certainly nothing wrong with that, but what's the thesis?
Short term? Long term? Is it just a China play? Short term or long term there?

For a long term hold, chart-wise Boyd looks better, coming off of a bearish reversal consolidation, around $26 and then breaking that collar (where I called it out as a GBA upgrade last month); but NIO could run on popularity and momo from the herd.
Untitled.jpg

Buffett dumped some Boyd, but he still owns a bunch.

The sale lowered Berkshire's holdings in BYD's total issued H-shares to 13.97% on Jan. 3 from 14.06%.

BYD led all brands in China's December EV sales with 234,598 electric cars including plug-in hybrids and pure EVs, more than quadruple Tesla's (NASDAQ:TSLA) sales in the same month.
 
Last edited:
I have a crazy day today I get my tooth cap. They guy said he likes to use no novacain when he goes back in... I dunno I need a bit. Then I have acupuncture same day. ugh!

--Boot Barn downgraded to Neutral from Outperform at Baird

--HeidelbergCement upgraded to Buy from Hold at HSBC 04:53 HDELY

--Auto Trader Group upgraded to Overweight from Equal Weight at Barclays » 04:36 ATDRY

--4D Molecular initiated with an Outperform at BMO Capital 04:26 FDMT
 
CymaBay price target raised to $19 from $12 at Piper Sandler 18:21 CBAY Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on CymaBay to $19 from $12 to reflect increased confidence in the company and seladelpar's commercial opportunity, while keeping an Overweight rating on the shares.CymaBay is the firm's top small cap pick for 2023 for several reasons, namely the recent raise and Kaken deal that removes the cash overhang, Phase 3 RESPONSE that is on track for reporting in Q3 2023, recent epidemiology data suggesting a larger addressable population for seladelpar versus previous predictions, CymaBay's NDA package that will include over 400 PBC patients in the safety database, and seladelpar that could be the most effective drug in 2L PBC givenits anti-inflammatory effect and benefit on itch reduction giving it a competitive edge.

Rio Tinto loses 'highly radioactive' capsule in Australia, Bloomberg reports
 
Catch-Up Upgrades/ stk already ahead of their est-

Olin price target raised to $70 from $65 at Barclays » 06:48 OLN Barclays analyst Michael… Hexcel price target raised to $70 from $60 at Wells Fargo 06:47 HXL Wells Fargo analyst…

Wells Fargo near-term cautious on Apple into upcoming Q1 earnings 06:51 AAPL
 
Flowserve upgraded to Buy at BofA on visibility and valuation 06:51 FLS

Xeris announces FDA grants orphan-drug exclusivity for Recorlev » 07:08 XERS Xeris Biopha

Intel's quarter points to some risk for AMD in Q1, says Morgan Stanley »

Genprex initiated with a Buy at Dawson James » 07:51 GNPX
 
You must log in or register to reply here.
Back
Top